Spero Therapeutics Stock Leadership
| SPRO Stock | USD 2.56 0.05 1.99% |
Below is a snapshot of Spero Therapeutics' ownership structure and how that base is positioned today. Institutional investors hold roughly 16.82% of Spero Therapeutics, while insiders own about 22.51%. Insider transaction patterns around earnings dates can reveal confidence or hedging behavior.
Insider Sentiment
SellingBuying
0 · Aggressively Selling
Spero Therapeutics' insiders appear positioned to sell. Overall insider sentiment for Spero Therapeutics appears strongly bearish.
Latest Trades
| 2026-02-06 | Esther Rajavelu | Disposed 87917 @ 2.36 | View | ||
| 2026-02-02 | Esther Rajavelu | Disposed 18442 @ 2.2 | View | ||
| 2025-11-07 | Esther Rajavelu | Disposed 40270 @ 2.37 | View | ||
| 2025-08-28 | Ankit Mahadevia | Disposed 6572 @ 1.97 | View |
Insider trading activity in Spero Therapeutics reflects internal positioning, transaction timing, and alignment between management behavior and market conditions, while remaining subject to formal disclosure requirements under securities law. Transaction motives are not always purely directional, which is why pattern analysis across multiple insiders strengthens the signal.
Spero |
Spero Therapeutics' Workforce Through the Years
Historical employee data for Spero Therapeutics indicates whether the business is scaling, restructuring, or stabilizing across different operating conditions. Disclosed headcount near about 40 employees warrants comparison with broader business results to identify scaling or restructuring trends. Reported workforce figures may vary across disclosures and time periods; aggregated or historical datasets can reflect different figures depending on reporting scope and methodology.Macro event markers
Management Team Effectiveness
SPRO has return on total asset (ROA) of 4.99% suggesting that the asset base is earning positive returns for the period. This is neither notably high nor low for the sector. Spero Therapeutics also reports a return on stockholder's equity (ROE) of 16.31%, suggesting that shareholder equity is earning positive returns for the period.Based on figures reported as of December 31, 2025, Common Stock Shares Outstanding is near current levels at 59.04 million.
Stock Institutional Investors
At micro-cap scale, institutional coverage and secondary-market liquidity are typically well established. The holder split in Spero Therapeutics separates passive index allocation from active institutional positioning. The business currently sits in the Health Care sector and the Pharmaceuticals, Biotechnology & Life Sciences industry. Watching turnover and volume trends alongside ownership data adds depth to the picture.
| Shares | The Informed Momentum Company (formerly Eam Investors) | 2025-12-31 | 218.1 K | Two Sigma Advisers, Llc | 2025-12-31 | 216.6 K | State Street Corp | 2025-12-31 | 210.2 K | Ionic Capital Management Llc | 2025-12-31 | 195.9 K | Gsa Capital Partners Llp | 2025-12-31 | 178.9 K | Intrepid Family Office Llc | 2025-12-31 | 165 K | Jane Street Group Llc | 2025-12-31 | 158.3 K | Sei Investments Co | 2025-12-31 | 132 K | Omers Administration Corp | 2025-12-31 | 131.1 K | Gsk Plc | 2025-12-31 | 9.2 M | Pfizer Inc | 2025-12-31 | 2.4 M |
Insider Trading Activities
Insider disclosures for Spero Therapeutics show how people closest to the business are behaving as market expectations change. At micro-cap scale, institutional coverage and secondary-market liquidity are typically well established. These records work best as context, not as standalone buy-or-sell signals.
Outstanding Bonds
Corporate bonds issued by Spero Therapeutics matter because they shape interest expense, maturity risk, and the flexibility management has during tighter credit conditions. Longer-dated obligations can improve financing stability, but they also leave investors more exposed if the underlying business weakens before the debt matures.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley Jul Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Shares in Circulation | First Issued 2016-09-30 | Previous Quarter 56.28 million | Current Value 59.37 million | Average Shares Outstanding 31.75 million | Quarterly Volatility 17.93 million |
Macro event markers
Holders Distribution
A large institutional presence around Spero Therapeutics deserves attention because well-resourced participants establish or unwind positions quickly enough to change the market character of the security. One practical risk is that institutions can own millions of shares, so concentrated selling can pressure the stock quickly once sentiment changes.
Market Cap and Value
Workforce Comparison
Spero Therapeutics is rated below average in number of employees compared to key competitors. The total workforce of Health Care industry is at this time estimated at about 557. Spero Therapeutics holds roughly 25 in number of employees claiming about 4% of equities under Health Care sector.
SPRO has Profit Margin (PM) of 13.0%. Similarly, it shows Operating Margin (OM) of 76.0%. Insider Trading History
The insider trade history for Spero Therapeutics reveals whether executives were buying or selling during key price moves. Sustained buying at different price levels is a stronger signal than routine scheduled sales under 10b5-1 plans.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2026-03-01 | 1.0 | 4 | 4 | 952,000 | 65,028 |
| 2025-03-01 | 0.4444 | 4 | 9 | 1,383,685 | 301,778 |
| 2024-03-01 | 1.0 | 6 | 6 | 1,554,164 | 229,741 |
| 2023-09-01 | 0.1667 | 1 | 6 | 266,000 | 58,261 |
| 2023-03-01 | 1.75 | 7 | 4 | 1,642,156 | 28,578 |
| 2022-09-01 | 1.6667 | 5 | 3 | 75,000 | 1,907,813 |
| 2021-12-01 | 3.0 | 6 | 2 | 423,493 | 16,000 |
| 2021-03-01 | 1.8 | 9 | 5 | 434,501 | 103,000 |
| 2020-12-01 | 0.7778 | 14 | 18 | 163,499 | 636,931 |
| 2020-09-01 | 0.5 | 3 | 6 | 3,821 | 7,642 |
| 2020-06-01 | 0.625 | 5 | 8 | 32,180 | 34,360 |
| 2020-03-01 | 2.0 | 8 | 4 | 363,928 | 86,966 |
| 2018-09-01 | 0.4286 | 6 | 14 | 102,822 | 21,352 |
| 2017-12-01 | 0.8438 | 27 | 32 | 7,433,362 | 29,309,446 |
Notable Stakeholders
Stakeholder analysis for Spero Therapeutics is useful because companies often face trade-offs among groups that want very different outcomes from the same business. In practice, stakeholder review supports awareness of the people and incentives that may be shaping key decisions behind the scenes.
| Esther Rajavelu | CEO and President, CFO, Chief Business Officer, Treasurer & Director | Profile | |
| Timothy Keutzer | COO | Profile | |
| Sheila Finan | Senior VP & Controller | Profile | |
| John Raymond | Senior Vice President of Finance & Business Operations | Profile | |
| Satyavrat CFA | CFO Treasurer | Profile | |
| James Brady | Chief Officer | Profile | |
| Ted Jenkins | VP Relations | Profile | |
| Ian Critchley | Head Microbiology | Profile | |
| Angela MD | VP Devel | Profile | |
| MBA MD | President, CoFounder | Profile | |
| Tamara LLM | Chief Secretary | Profile | |
| Susannah Walpole | Head Operations | Profile | |
| David Hong | Senior Development | Profile |
Management Information & Data Sources
Spero Therapeutics is a micro-cap company across Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Leadership tenure and executive continuity help assess whether strategic vision is being maintained across cycles. Executive background and prior track record clarify current strategic priorities. CEO is Esther Rajavelu with 25 employees and 13 reported executives.
Spero Therapeutics analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Insider and management fields are mapped from published filings and company disclosures.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
Workforce Efficiency and Productivity
Workforce efficiency at Spero Therapeutics reveals how effectively labor resources are being converted into revenue and earnings over time. When applied, manpower metrics highlight whether growth is being supported by better productivity or by heavier staffing costs.
Spero Therapeutics Manpower Efficiency
Return on Spero Therapeutics Manpower
| Revenue Per Employee | 2.4M | |
| Revenue Per Executive | 4.6M | |
| Net Income Per Employee | 342.9K | |
| Net Income Per Executive | 659.4K | |
| Working Capital Per Employee | 2.3M | |
| Working Capital Per Executive | 4.5M |